Innovation is an integral part of the company’s culture, and present in its products, services and processes.
In 2020, we invested R$ 104 million in innovation and celebrated two important achievements that reinforced our vocation to innovate: we obtained approval of a Phase II clinical trial from the FDA (Food and Drug Administration) for an experimental oral therapy used for treating vitiligo that contains an innovative plant extract; and we inaugurated the In Silico Prediction, Information & Research (InSPIRe Lab) Laboratory for implementing data science, analytics and machine learning tools to accelerate decision making in the different areas that are dedicated to the innovation process in Aché.
The InSPIRe Lab aims to encourage the use of data science approaches to make the innovation process more agile and assertive. The laboratory format structure will also enable the development of new algorithms and computing tools, which will adopt a purposeful and scientific approach to the needs of the innovation areas. It will also ensure that Aché is more involved with startup ecosystems.
Introduction of worldwide existing assets in Brazil or promotion of incremental improvements.+
Efficient therapeutic responses in high- complexity diseases when compared to synthetic manufacture originals.+